News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Key Points According to a Form 4 filing, a director at Brixmor reported selling 9,000 shares for $267,300 on August 12. The sale reduced the director's direct equity holdings by 23%. The transaction was executed entirely through direct ownership of common stock.10 stocks we …
Michael B Berman, a director at Brixmor Property Group Inc. (NASDAQ:BRX), sold 9,000 shares of common stock for $267,300 on August 12, 2026, at an average price of $29.7 per share. Following the transaction, Berman directly holds 30,702 shares. The company's stock trades at …
Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. have reported a beneficial ownership of 1,489,443 shares of Inhibrx Biosciences, Inc. (INBX) common stock, representing 9.99% of the class. This stake includes common shares and pre-funded warrants, with the exercise of …
Schonfeld Strategic Advisors LLC has disclosed a 5.33% beneficial ownership stake in Inhibrx Biosciences, Inc. (INBX) through a Schedule 13G filing. This amounts to 781,678 shares of common stock, representing 5.33% of the 14,671,186 shares outstanding as of May 8, 2026. Schonfeld maintains sole …
Inhibrx Biosciences (NASDAQ:INBX) experienced a share price drop after missing earnings estimates, opening at $91.80, down from its previous close of $97.01. The company reported an EPS of $(2.34) against an estimated $(2.28). Analyst ratings for INBX are mixed, with an average "Hold" rating …
Inhibrx Biosciences (NASDAQ:INBX) has received a consensus "Hold" recommendation from brokerages, with an average 12-month price target of $150.00. The company recently reported a quarterly EPS of -$2.34, missing analyst estimates, and institutional investors now own 82.46% of the stock. BlackRock Inc. notably acquired …
Inhibrx Biosciences (NASDAQ:INBX) reported a quarterly loss of $2.34 per share, missing analysts' consensus estimates by $0.06. Following the announcement, the stock fell 1.4% to $97.01. Despite mixed analyst sentiment resulting in a "Hold" rating, institutional investors hold a significant 82.46% of the company's …
This article reports on the filing of a Form 8K by Inhibrx Biosciences Inc. for August 13. The brief notice highlights the company's regulatory submission without providing further details on its content. It includes the stock symbol INBX, which saw a slight decrease.
Inhibrx Biosciences (INBX) reported a net loss of $70.1 million for the first half of 2026, with no revenue, while holding $133.3 million in cash and equivalents. Despite the losses, the company advanced its clinical pipeline, with ozekibart achieving a statistically significant progression-free survival …
Inhibrx reported a net loss of $36.7 million in Q2 2026, with R&D expenses at $23.9 million and G&A at $8.3 million. The company secured an amended loan with Oxford Finance for up to $325.0 million, with $100.0 million already funded. The FDA accepted …
An insider at Brixmor Property Group Inc. (BRX) has filed a Form 144 notice to sell 9,000 shares of common stock on the NYSE for an aggregate proposed price of $267,975. The sale is planned for on or after August 12, 2026, through Northern …
This page provides comprehensive financial information for Brixmor Property Group Inc. (BRX), including its current stock price, historical data, performance metrics against the S&P 500, earnings trends, analyst ratings, and valuation measures. Brixmor owns and operates a national portfolio of open-air shopping centers, with …
Wall Street Zen has upgraded Inhibrx Biosciences (NASDAQ:INBX) from a "Sell" to a "Hold" rating, bringing the consensus rating for the stock to "Hold" with an average price target of $150. This upgrade comes despite the company reporting a quarterly loss of $2.15 per …
Inhibrx Biosciences (INBX) is scheduled to announce its Q2 2026 earnings before market open on Wednesday, August 12th. Analysts predict a loss of $2.28 per share, following a previous quarter where the company missed expectations with a $2.15 per share loss. The stock, which …
This article analyzes Inhibrx Biosciences Inc Com (NASDAQ: INBX), highlighting positive near-term sentiment within a long-term strength context, despite a mid-term weak bias. It identifies elevated downside risk and provides AI-generated institutional trading strategies for different risk profiles. The analysis includes position trading, momentum …
This page provides news and updates for Brixmor Property Group (BRX) investors, covering financial results, operational trends, and corporate activities. Recent news includes an expanded partnership with EVgo for EV charging stations and strong second-quarter 2026 results with increased Nareit FFO guidance. The company …
Citi has initiated coverage on Brixmor Property Group Inc (BRX.US) with a Hold rating. The firm has also set a target price of $34 for the company's stock.
Citigroup has reiterated its "Neutral" rating on Brixmor Property Group. The article does not provide specific details from Citigroup's report or the rationale behind the maintained rating.
EVgo Inc. and Brixmor Property Group Inc. are expanding their partnership to install over 500 fast charging stalls at Brixmor shopping centers across the U.S. This initiative will bring EVgo chargers to at least 90 Brixmor locations, covering more than 25% of their portfolio, …
EVgo and Brixmor Property Group are expanding their partnership to add over 500 new EVgo fast charging stalls at more than 90 Brixmor shopping centers across the U.S., including locations in Florida, Illinois, Minnesota, New Jersey, Pennsylvania, and Texas. This collaboration aims to increase …
Bank of America Corporation has reported a beneficial ownership of 857,318 shares of Inhibrx Biosciences (INBX) common stock, which represents 5.9% of the class. This ownership is held through various affiliated entities, including BofA Securities, Inc., Bank of America, N.A., Merrill Lynch International, Merrill …
BofA Securities has raised its price target for Brixmor Property Group (BRX) to $35 from $34. This adjustment comes after Brixmor Property Group reported its Q2 2026 earnings, which showed a rise in Nareit FFO and revenue. The company also declared a quarterly cash …
Quantinno Capital Management LP increased its stake in Brixmor Property Group Inc. (NYSE:BRX) by 9.5% in the first quarter, acquiring 45,809 additional shares to hold a total of 526,680 shares valued at approximately $15.2 million. Institutional investors now collectively own 98.43% of the company's …
Brixmor Property (BRX) is highlighted as a potentially strong investment for income-focused investors due to its consistent dividend payouts. The company, which operates shopping centers, offers a dividend yield of 3.9%, exceeding both its industry average and the S&P 500. With a history of …
Brixmor Property Group has acquired the 221,612-square-foot Mayfair Shopping Center in Commack, New York, for $70 million. The center, built in 1958, is anchored by Lidl, Planet Fitness, and PGA TOUR Superstore, and includes other tenants like Gap, Sephora, and J.Crew Factory. Cronheim Mortgage …
Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Brixmor Property Group (BRX) has drawn fresh attention after reporting second quarter 2026 earnings and affirming its quarterly dividend, giving investors new information on both cash generation …
The article analyzes the institutional confidence score for Inhibrx Biosciences Inc (INBX), which currently stands at 7.00, placing it 80th in its industry. Institutional shareholding has increased to 84.51%, with Andreas Halvorsen being the largest shareholder. The report also lists other significant institutional shareholders …
Inhibrx Biosciences (INBX) recently expanded its credit facility to $500 million, leading to a reassessment of its valuation by investors, despite a strong year-to-date return. The company's high price-to-book ratio of 55.6x, compared to an industry average of 2.4x, reflects its negative equity and …
Search by ticker symbol or company name and select a result to open its chart.